These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 38566385)
1. Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective. Shukla D; Suryavanshi A; Bharti SK; Asati V; Mahapatra DK Curr Top Med Chem; 2024 Apr; ():. PubMed ID: 38566385 [TBL] [Abstract][Full Text] [Related]
2. Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs. Varadharajan A; Davis AD; Ghosh A; Jagtap T; Xavier A; Menon AJ; Roy D; Gandhi S; Gregor T J Neurosci Rural Pract; 2023; 14(4):566-573. PubMed ID: 38059250 [TBL] [Abstract][Full Text] [Related]
3. Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab. Chin E; Jaqua E; Safaeipour M; Ladue T Cureus; 2022 Nov; 14(11):e31065. PubMed ID: 36475205 [TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease and its treatment-yesterday, today, and tomorrow. Kim AY; Al Jerdi S; MacDonald R; Triggle CR Front Pharmacol; 2024; 15():1399121. PubMed ID: 38868666 [TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs. Thakral S; Yadav A; Singh V; Kumar M; Kumar P; Narang R; Sudhakar K; Verma A; Khalilullah H; Jaremko M; Emwas AH Ageing Res Rev; 2023 Jul; 88():101960. PubMed ID: 37224884 [TBL] [Abstract][Full Text] [Related]
6. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review. Chowdhury S; Chowdhury NS Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139 [TBL] [Abstract][Full Text] [Related]
7. Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease. Saeedi M; Mehranfar F Recent Pat Biotechnol; 2022; 16(2):102-121. PubMed ID: 35236274 [TBL] [Abstract][Full Text] [Related]
8. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568 [TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446 [TBL] [Abstract][Full Text] [Related]
10. Navigating the Alzheimer's Treatment Landscape: Unraveling Amyloid-Beta Complexities and Pioneering Precision Medicine Approaches. Patwekar M; Patwekar F; Khan S; Sharma R; Kumar D Curr Top Med Chem; 2024 Apr; ():. PubMed ID: 38644708 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion. Esquer A; Blanc F; Collongues N Neurol Ther; 2023 Dec; 12(6):1883-1907. PubMed ID: 37812325 [TBL] [Abstract][Full Text] [Related]
12. The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention. Tolar M; Hey JA; Power A; Abushakra S Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473975 [TBL] [Abstract][Full Text] [Related]
13. Advances in Understanding and Managing Alzheimer's Disease: From Pathophysiology to Innovative Therapeutic Strategies. Rathee S; Sen D; Pandey V; Jain SK Curr Drug Targets; 2024 Jul; ():. PubMed ID: 39039673 [TBL] [Abstract][Full Text] [Related]
14. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies. Imbimbo BP; Ippati S; Watling M; Imbimbo C Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644 [TBL] [Abstract][Full Text] [Related]
15. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
16. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab. Shi M; Chu F; Zhu F; Zhu J Front Aging Neurosci; 2022; 14():870517. PubMed ID: 35493943 [TBL] [Abstract][Full Text] [Related]
17. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. Morató X; Pytel V; Jofresa S; Ruiz A; Boada M Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569 [TBL] [Abstract][Full Text] [Related]
18. Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies. Buccellato FR; D'Anca M; Tartaglia GM; Del Fabbro M; Scarpini E; Galimberti D Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762203 [TBL] [Abstract][Full Text] [Related]
19. Anti-amyloid Antibody Therapies for Alzheimer's Disease. Park KW Nucl Med Mol Imaging; 2024 Jun; 58(4):227-236. PubMed ID: 38932758 [TBL] [Abstract][Full Text] [Related]